Latest Articles
Insurance coverage for GSK's Jemperli expanded to 1st-line endometrial cancer in Korea - koreabiomed.com
Insurance coverage for GSK's Jemperli expanded to 1st-line endometrial cancer in Korea koreabiomed.com
Published: Sept. 29, 2025, 8:16 a.m.
Jemperli Scores Korean Coverage Ahead of Keytruda in Endometrial Cancer - NAVLIN DAILY
Jemperli Scores Korean Coverage Ahead of Keytruda in Endometrial Cancer NAVLIN DAILY
Published: Sept. 22, 2025, 11:27 p.m.
Latecomer Jemperli wins reimbursement race against Keytruda for endometrial cancer in Korea - koreabiomed.com
Latecomer Jemperli wins reimbursement race against Keytruda for endometrial cancer in Korea koreabiomed.com
Published: Sept. 19, 2025, 4:21 a.m.
Risk of Abortion and Ectopic Pregnancy in Women with a History of Polycystic Ovary Syndrome: A Nationwide Population-Based Cohort Study.
Objectives: The purpose of this retrospective cohort study was to ascertain the risk of abortion, ectopic pregnancy and hydatidiform mole development in women with polycystic ovary syndrome (PCOS) using data …
Published: Sept. 7, 2025, midnight
TiumBio to present positive merigolix phase 2 results at ESHRE 2025 - koreabiomed.com
TiumBio to present positive merigolix phase 2 results at ESHRE 2025 koreabiomed.com
Published: June 26, 2025, 1:33 a.m.
AZ redefines endometrial and ovarian cancer playbook - koreabiomed.com
AZ redefines endometrial and ovarian cancer playbook koreabiomed.com
Published: June 25, 2025, 12:05 a.m.
SNUBH study finds lymph node dissection unnecessary in some endometrial cancer cases - koreabiomed.com
SNUBH study finds lymph node dissection unnecessary in some endometrial cancer cases koreabiomed.com
Published: June 5, 2025, 3:23 a.m.
MSD launches phase 3 Keytruda combo trial in tough-to-treat endometrial cancer in Korea - koreabiomed.com
MSD launches phase 3 Keytruda combo trial in tough-to-treat endometrial cancer in Korea koreabiomed.com
Published: May 30, 2025, 1:52 a.m.
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial - koreabiomed.com
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial koreabiomed.com
Published: May 7, 2025, 6:51 a.m.
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence.
To investigate the association between the duration of levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer risk in Korean women.
Published: March 13, 2025, midnight
Link copied to clipboard!